Detalhe da pesquisa
1.
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell
; 185(3): 563-575.e11, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120664
2.
Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature
; 606(7912): 172-179, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545680
3.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
N Engl J Med
; 384(12): 1125-1135, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33577729
4.
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
J Pathol
; 261(3): 349-360, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667855
5.
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Future Oncol
; 20(7): 351-360, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994649
6.
TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Nature
; 554(7693): 544-548, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29443960
7.
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature
; 606(7914): E5, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641605
8.
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Oncologist
; 27(3): e223-e232, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274723
9.
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy.
BJU Int
; 129(4): 463-469, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33866683
10.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 872-882, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991512
11.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(4): 525-537, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721560
12.
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Br J Cancer
; 124(7): 1214-1221, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33473164
13.
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
J Urol
; 205(2): 414-419, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32935617
14.
Dermatologic infections in cancer patients treated with checkpoint inhibitors.
J Am Acad Dermatol
; 85(6): 1528-1536, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33744355
15.
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Cancer
; 126(11): 2597-2606, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32208524
16.
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
Cancer
; 126(20): 4532-4544, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32767682
17.
Utility of Routine Preoperative 18F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.
J Urol
; 204(2): 254-259, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32134343
18.
Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience.
J Urol
; 204(4): 677-684, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32294398
19.
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
J Urol
; 204(6): 1173-1179, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32552295
20.
Antibody-Drug Conjugates in Urothelial Carcinomas.
Curr Oncol Rep
; 22(2): 13, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32008109